var data={"title":"Carvedilol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Carvedilol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5830?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=carvedilol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Carvedilol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=carvedilol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Carvedilol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146697\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Coreg;</li>\n      <li>Coreg CR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146698\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Carvedilol;</li>\n      <li>Auro-Carvedilol;</li>\n      <li>Dom-Carvedilol;</li>\n      <li>JAMP-Carvedilol;</li>\n      <li>Mylan-Carvedilol;</li>\n      <li>Novo-Carvedilol;</li>\n      <li>PMS-Carvedilol;</li>\n      <li>RAN-Carvedilol;</li>\n      <li>ratio-Carvedilol</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146742\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihypertensive;</li>\n      <li>\n        Beta-Blocker With Alpha-Blocking Activity</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146702\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Reduce dosage if heart rate drops to &lt;55 beats/minute.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> 6.25 mg twice daily; if tolerated, dose should be maintained for 1 to 2 weeks, then increased to 12.5 mg twice daily. If necessary, dosage may be increased to a maximum of 25 mg twice daily after 1 to 2 weeks. Usual dosage range (ASH/ISH [Weber, 2014]): 6.25 to 25 mg twice daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Initial: 20 mg once daily, if tolerated, dose should be maintained for 1 to 2 weeks then increased to 40 mg once daily if necessary; if this dose is tolerated, maintain for 1 to 2 weeks then, if necessary, increase to 80 mg once daily; maximum dose: 80 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Heart failure:</b> Oral: <b>Note:</b> Initiate only in stable patients or hospitalized patients after volume status has been optimized and IV diuretics, vasodilators, and inotropic agents have all been successfully discontinued. Caution should be used when initiating in patients who required inotropes during their hospital course. Increase dose gradually and monitor for congestive signs and symptoms of HF making every effort to achieve target dose shown to be effective (HFSA [Lindenfeld, 2010]; Packer, 1996; ACCF/AHA [Yancy, 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release: </i>3.125 mg twice daily for 2 weeks; if this dose is tolerated, may increase to 6.25 mg twice daily. Double the dose every 2 weeks to the highest dose tolerated by patient. (Prior to initiating therapy, other heart failure medications should be stabilized and fluid retention minimized.)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum recommended dose:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Mild to moderate heart failure:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;85 kg: 25 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;85 kg: 50 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Severe heart failure: 25 mg twice daily (Packer, 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Initial: 10 mg once daily for 2 weeks; if the dose is tolerated, increase dose to 20 mg, 40 mg, and 80 mg over successive intervals of at least 2 weeks. Maintain on lower dose if higher dose is not tolerated. <b>Note:</b> The 2013 ACCF/AHA heart failure guidelines recommend a maximum dose of 80 mg once daily (Yancy, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Left ventricular dysfunction following MI:</b> Oral: <b>Note:</b> Should be initiated only after patient is hemodynamically stable and fluid retention has been minimized.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Immediate release:</i> Initial 3.125 to 6.25 mg twice daily; increase dosage incrementally (ie, from 6.25 to 12.5 mg twice daily) at intervals of 3 to 10 days, based on tolerance, to a target dose of 25 mg twice daily. <b>Note:</b> The 2013 ACCF/AHA heart failure guidelines recommend a maximum dose of 50 mg twice daily (Yancy, 2013].</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Extended release:</i> Initial: 10 to 20 mg once daily; increase dosage incrementally at intervals of 3 to 10 days, based on tolerance, to a target dose of 80 mg once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Angina pectoris (off-label use):</b> Oral: <i>Immediate release:</i> 25 to 50 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Atrial fibrillation (rate control) (off-label use):</b> Usual maintenance dose: 3.125 to 25 mg twice daily (AHA/ACC/HRS [January, 2014]). In patients with heart failure, the initial dose of 3.125 mg twice daily may be increased at 2-week intervals to a target dose of 25 mg twice daily (50 mg twice daily for patients weighing &gt;85 kg) (Khand, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Gastroesophageal variceal hemorrhage prophylaxis in patients with cirrhosis (alternative agent) (off-label use):</b> Oral: Initial: 3.125 mg twice daily or 6.25 mg <b>once</b> daily; to achieve a resting heart rate of 55 to 60 bpm (if heart rate used for titration), may increase after 3 to 7 days to a maximum dose of 6.25 mg twice daily or 12.5 mg <b>once</b> daily (some patients [eg, with Child-Pugh class A cirrhosis or those with persistent arterial hypertension] may receive a maximum dose of 12.5 mg twice daily) (Baiges 2017; Bhardwaj 2017; Garcia-Tsao 2016; LaBrecque 2014; Sanyal 2018; Tripathi 2009). <b>Note:</b> Higher doses (eg, &gt;12.5 mg/day) may decrease arterial pressure and should not be used in patients with refractory ascites. Use is not recommended for recurrent variceal hemorrhage (Garcia-Tsao 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Conversion from immediate release to extended release (Coreg CR):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Current dose immediate-release tablets 3.125 mg twice daily: Convert to extended-release capsules 10 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Current dose immediate-release tablets 6.25 mg twice daily: Convert to extended-release capsules 20 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Current dose immediate-release tablets 12.5 mg twice daily: Convert to extended-release capsules 40 mg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Current dose immediate-release tablets 25 mg twice daily: Convert to extended-release capsules 80 mg once daily</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146703\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Refer to adult dosing. In the management of hypertension, consider lower initial doses and titrate to response (Aronow, 2011). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146704\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary; not significantly cleared by hemodialysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146705\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146669\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as phosphate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coreg CR: 10 mg, 20 mg, 40 mg, 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 40 mg, 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coreg: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 3.125 mg, 6.25 mg, 12.5 mg, 25 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146653\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23610321\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146673\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Administer with food to minimize the risk of orthostatic hypotension. Extended-release capsules and its contents should not be crushed, chewed, or divided. Capsules may be opened and its contents sprinkled on applesauce for immediate use. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146672\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hypertension:</b> Management of hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The 2014 guideline for the management of high blood pressure in adults (Eighth Joint National Committee [JNC 8]) recommends initiation of pharmacologic treatment to lower blood pressure for the following patients (JNC 8 [James, 2013]):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Patients &ge;60 years of age, with systolic blood pressure (SBP) &ge;150 mm Hg or diastolic blood pressure (DBP) &ge;90 mm Hg. Goal of therapy is SBP &lt;150 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Patients &lt;60 years of age, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull;\t Patients &ge;18 years of age with diabetes, with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">&bull; Patients &ge;18 years of age with chronic kidney disease (CKD), with SBP &ge;140 mm Hg or DBP &ge;90 mm Hg. Goal of therapy is SBP &lt;140 mm Hg and DBP &lt;90 mm Hg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In patients with CKD, regardless of race or diabetes status, the use of an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) as initial therapy is recommended to improve kidney outcomes. In the general non-black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic, calcium channel blocker, ACEI, or ARB. In the general black population (without CKD) including those with diabetes, initial antihypertensive treatment should consist of a thiazide-type diuretic or a calcium channel blocker <b>instead of</b> an ACEI or ARB.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Heart failure:</b> Mild to severe chronic heart failure of ischemic or cardiomyopathic origin (usually in addition to standard therapy [eg, diuretics, ACE inhibitors]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">The ACCF/AHA 2013 heart failure guidelines recommend the use of 1 of the 3 beta blockers (ie, bisoprolol, carvedilol, or extended-release metoprolol succinate) for all patients with recent or remote history of MI or ACS and reduced ejection fraction (rEF) to reduce mortality, for all patients with rEF to prevent symptomatic HF (even if no history of MI), and for all patients with current or prior symptoms of HF with reduced ejection fraction (HFrEF), unless contraindicated, to reduce morbidity and mortality (Yancy, 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Left ventricular dysfunction following myocardial infarction (MI):</b> Left ventricular dysfunction following MI (clinically stable with LVEF &le;40%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25724865\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Atrial fibrillation (rate control); Chronic stable angina; Gastroesophageal variceal hemorrhage prophylaxis in patients with cirrhosis; Non-ST-elevation acute coronary syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146750\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Carvedilol may be confused with atenolol, captopril, carbidopa, carteolol</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Coreg may be confused with Corgard, Cortef, Cozaar</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146660\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Frequency ranges include data from hypertension and heart failure trials. Higher rates of adverse reactions have generally been noted in patients with heart failure. However, the frequency of adverse effects associated with placebo is also increased in this population. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypotension (9% to 20%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Dizziness (2% to 32%), fatigue (4% to 24%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hyperglycemia (5% to 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Weight gain (10% to 12%), diarrhea (1% to 12%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (7% to 11%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Bradycardia (2% to 10%), syncope (3% to 8%), peripheral edema (1% to 7%), generalized edema (5% to 6%), angina (1% to 6%), dependent edema (&le;4%), AV block, cerebrovascular accident, hypertension, hyper-/hypovolemia, orthostatic hypotension, palpitation </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (5% to 8%), depression, fever, hypoesthesia, hypotonia, insomnia, malaise, somnolence, vertigo </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hypercholesterolemia (1% to 4%), hypertriglyceridemia (1%), diabetes mellitus, gout, hyperkalemia, hyperuricemia, hypoglycemia, hyponatremia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (2% to 9%), vomiting (1% to 6%), abdominal pain, melena, periodontitis, weight loss </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Impotence </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic: Anemia, prothrombin decreased, purpura, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Alkaline phosphatase increased (1% to 3%), GGT increased, transaminases increased </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (2% to 7%), arthralgia (1% to 6%), arthritis, muscle cramps, paresthesia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ocular: Blurred vision (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: BUN increased (&le;6%), nonprotein nitrogen increased (6%), albuminuria, creatinine increased, glycosuria, hematuria, renal insufficiency </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough (5% to 8%), nasopharyngitis (4%), rales (4%), dyspnea (&gt;3%), pulmonary edema (&gt;3%), rhinitis (2%), nasal congestion (1%), sinus congestion (1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Injury (3% to 6%), allergy, flu-like syndrome, sudden death </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (limited to important or life-threatening): Anaphylactoid reaction, alopecia, angioedema, aplastic anemia, amnesia, asthma, bronchospasm, bundle branch block, cholestatic jaundice, concentration decreased, diaphoresis, erythema multiforme, exfoliative dermatitis, GI hemorrhage, HDL decreased, hearing decreased, hyperbilirubinemia, hypersensitivity reaction, hypokalemia, hypokinesia, interstitial pneumonitis, leukopenia, libido decreased, migraine, myocardial ischemia, nervousness, neuralgia, nightmares, pancytopenia, paresis, peripheral ischemia, photosensitivity, pruritus, rash (erythematous, maculopapular, and psoriaform), respiratory alkalosis, seizure, Stevens-Johnson syndrome, tachycardia, tinnitus, toxic epidermal necrolysis, urinary incontinence, urticaria, xerostomia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146676\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious hypersensitivity to carvedilol or any component of the formulation; decompensated cardiac failure requiring intravenous inotropic therapy; bronchial asthma or related bronchospastic conditions; second- or third-degree AV block, sick sinus syndrome, and severe bradycardia (except in patients with a functioning artificial pacemaker); cardiogenic shock; severe hepatic impairment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Documentation of allergenic cross-reactivity for drugs alpha/beta adrenergic blocking agents is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146657\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bradycardia: May occur; reduce dosage if heart rate drops to &lt;55 beats/minute. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha<sub>1</sub>-blockers; there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery. Instruct patients to inform ophthalmologist of carvedilol use when considering eye surgery. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypotension/syncope: Symptomatic hypotension with or without syncope may occur with carvedilol (usually within the first 30 days of therapy); close monitoring of patient is required especially with initial dosing and dosing increases; blood pressure must be lowered at a rate appropriate for the patient's clinical condition. Initiation with a low dose, gradual up-titration, and administration with food may help to decrease the occurrence of hypotension or syncope. Advise patients to avoid driving or other hazardous tasks during initiation of therapy due to the risk of syncope. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Angina: Use with caution in patients suspected of having Prinzmetal variant angina.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms (eg, sweating, anxiety, tachycardia). In patients with heart failure and diabetes, use of carvedilol may worsen hyperglycemia; may require adjustment of antidiabetic agents. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): Heart failure patients may experience a worsening of renal function (rare); risk factors include ischemic heart disease, diffuse vascular disease, underlying renal dysfunction, and/or systolic BP &lt;100 mm Hg. Initiate cautiously and monitor for possible deterioration in patient status (eg, symptoms of HF). Worsening heart failure or fluid retention may occur during upward titration; dose reduction or temporary discontinuation may be necessary. Adjustment of other medications (ACE inhibitors and/or diuretics) may also be required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; use is contraindicated in patients with severe hepatic impairment. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Peripheral vascular disease (PVD): May precipitate or aggravate symptoms of arterial insufficiency in patients with PVD; use with caution and monitor for progression of arterial obstruction. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pheochromocytoma (untreated): Use with caution; adequate alpha-blockade should be initiated prior to use of any beta-blocker.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Psoriasis: Beta-blocker use has been associated with induction or exacerbation of psoriasis, but cause and effect have not been firmly established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If hyperthyroidism is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Bradycardia may be observed more frequently in elderly patients (&gt;65 years of age); dosage reductions may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson, 2002; Lucente 2000; Shelley, 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade, 1986; CDC, 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt withdrawal: Beta-blocker therapy should not be withdrawn abruptly (particularly in patients with CAD), but gradually tapered to avoid acute tachycardia, hypertension, and/or ischemia. Severe exacerbation of angina, ventricular arrhythmias, and myocardial infarction (MI) have been reported following abrupt withdrawal of beta-blocker therapy. Temporary and prompt resumption of beta-blocker therapy may be indicated with worsening of angina or acute coronary insufficiency.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Major surgery: Chronic beta-blocker therapy should not be routinely withdrawn prior to major surgery.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146735\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146662\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9208&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Afatinib.  Management: Per US labeling: reduce afatinib by 10mg if not tolerated.  Per Canadian labeling: avoid combination if possible; if used, administer the P-gp inhibitor simultaneously with or after the dose of afatinib.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Some beta-adrenoceptor mediated effects of Alpha-/Beta-Agonists (Direct-Acting), including anti-anaphylactic effects of epinephrine, may be diminished by Beta-Blockers.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the Alpha2-Agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.<b> Exceptions: </b>Apraclonidine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May decrease the serum concentration of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Betrixaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban.  Management: Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilastine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bilastine.  Management: Consider alternatives when possible; bilastine should be avoided in patients with moderate to severe renal insufficiency who are receiving p-glycoprotein inhibitors.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bretylium: May enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Bepridil.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May increase the serum concentration of Carvedilol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Carvedilol may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: May enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inhibitors in patients treated with doxorubicin whenever possible.  One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Edoxaban.  Management: See full monograph for details. Reduced doses are recommended for patients receiving edoxaban for venous thromboembolism in combination with certain inhibitors. Similar dose adjustment is not recommended for edoxaban use in atrial fibrillation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives. <b> Exceptions: </b>Nicergoline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and beta-blockers if possible. If coadministration is necessary, patients should have overnight continuous ECG monitoring conducted after the first dose of fingolimod. Monitor patients for bradycardia.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grass Pollen Allergen Extract (5 Grass Extract): Beta-Blockers may enhance the adverse/toxic effect of Grass Pollen Allergen Extract (5 Grass Extract). More specifically, Beta-Blockers may inhibit the ability to effectively treat severe allergic reactions to Grass Pollen Allergen Extract (5 Grass Extract) with epinephrine.  Some other effects of epinephrine may be unaffected or even enhanced (e.g., vasoconstriction) during treatment with Beta-Blockers. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Beta-Blockers may enhance the hypoglycemic effect of Insulins. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naldemedine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Naloxegol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiCARdipine: May enhance the hypotensive effect of Carvedilol. NiCARdipine may precipitate signs of heart failure in susceptible patients on Carvedilol NiCARdipine may increase the serum concentration of Carvedilol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: May enhance the hypotensive effect of Beta-Blockers. NIFEdipine may enhance the negative inotropic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioids (Anilidopiperidine): May enhance the bradycardic effect of Beta-Blockers. Opioids (Anilidopiperidine) may enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Ranolazine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: May enhance the bradycardic effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reserpine: May enhance the hypotensive effect of Beta-Blockers.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.<b> Exceptions: </b>Rifabutin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAXIMin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of RifAXIMin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivastigmine: May enhance the bradycardic effect of Beta-Blockers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents. Management: Ruxolitinib Canadian product labeling recommends avoiding use with bradycardia-causing agents to the extent possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.<b> Exceptions: </b>Citalopram; Escitalopram; FluvoxaMINE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terlipressin: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Venetoclax.  Management: Reduce the venetoclax dose by at least 50% in patients requiring these combinations.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146692\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Food decreases rate but not extent of absorption. Management: Administration with food minimizes risks of orthostatic hypotension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146680\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Adverse events, such as fetal/neonatal bradycardia, hypoglycemia, and reduced birth weight, have been observed following in utero exposure to beta-blockers as a class. Adequate facilities for monitoring infants at birth is generally recommended.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Untreated chronic maternal hypertension and preeclampsia are also associated with adverse events in the fetus, infant, and mother (ACOG 2015; Magee 2014). Although beta-blockers may be used when treatment of hypertension or heart failure in pregnancy is indicated, agents other than carvedilol are preferred (ACOG 2013; ESC [Regitz-Zagrosek 2011]; Magee 2014).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10162397\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if carvedilol is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Breastfeeding is not recommended for women with heart failure related to peripartum cardiomyopathy due to the high metabolic demands of lactation and breastfeeding (ESC [Regitz-Zagrosek 2011]; Sliwa 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146681\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Should be taken with food to minimize the risk of orthostatic hypotension.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146667\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure (base need for dosage increase on trough blood pressure measurements and for tolerance on standing systolic pressure 1 hour after dosing); renal studies, BUN, liver function; blood glucose in diabetics; in patients with increased risk for developing renal dysfunction, monitor during dosage titration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146656\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">As a racemic mixture, carvedilol has nonselective beta-adrenoreceptor and alpha-adrenergic blocking activity. No intrinsic sympathomimetic activity has been documented. Associated effects in hypertensive patients include reduction of cardiac output, exercise- or beta-agonist-induced tachycardia, reduction of reflex orthostatic tachycardia, vasodilation, decreased peripheral vascular resistance (especially in standing position), decreased renal vascular resistance, reduced plasma renin activity, and increased levels of atrial natriuretic peptide. In CHF, associated effects include decreased pulmonary capillary wedge pressure, decreased pulmonary artery pressure, decreased heart rate, decreased systemic vascular resistance, increased stroke volume index, and decreased right atrial pressure (RAP).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146675\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Antihypertensive effect:  Alpha-blockade: Within 30 minutes; Beta-blockade: Within 1 hour </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak antihypertensive effect: ~1 to 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Rapid and extensive, but with large first pass effect; first pass effect is stereoselective with R(+) enantiomer achieving plasma concentrations 2 to 3 times higher than S(-) enantiomer; delayed with food </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 115 L; distributes into extravascular tissues  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;98%, primarily to albumin </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively (98%) hepatic, via CYP2C9, 2D6, 3A4, 2C19, 1A2, and 2E1 (2% excreted unchanged); metabolized predominantly by aromatic ring oxidation and glucuronidation; oxidative metabolites undergo conjugation via glucuronidation and sulfation; three active metabolites (4-hydroxyphenyl metabolite is 13 times more potent than parent drug for beta-blockade, however, active metabolites achieve plasma concentrations of only 1/10 of those for carvedilol); first-pass effect; plasma concentrations in the elderly and those with cirrhotic liver disease are 50% and 4 to 7 times higher, respectively. Metabolism is subject to genetic polymorphism; CYP2D6 poor metabolizers have a 2- to 3-fold higher plasma concentration of the R(+) enantiomer and a 20% to 25% increase in the S(-) enantiomer compared to extensive metabolizers. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Immediate release: ~25% to 35% (due to significant first-pass metabolism); Extended release: ~85% of immediate release; high-fat meal increases AUC and C<sub>max</sub> ~20%; bioavailability is increased in patients with CHF </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children 6 weeks to 3.5 years (n=8): 2.2 hours (Laer 2002) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 5.5 to 19 years (n=7): 3.6 hours (Laer 2002) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults 7 to 10 hours; some have reported lower values: Adults 24 to 37 years (n=9): 5.2 hours (Laer 2002) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">R(+)-carvedilol: 5 to 9 hours </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">S(-)-carvedilol: 7 to 11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Extended release: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces; urine (&lt;2%, unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146679\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Carvedilol Phosphate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $297.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $297.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $297.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $297.28</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Coreg CR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $330.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (30): $330.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (30): $330.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">80 mg (30): $330.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Carvedilol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.125 mg (100): $213.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg (100): $213.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $213.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $213.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Coreg Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.125 mg (100): $575.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6.25 mg (100): $575.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg (100): $575.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $575.71</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F146682\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alvelol (KR);</li>\n      <li>Arlec (TR);</li>\n      <li>Artist (JP);</li>\n      <li>Avernol (ET, MT, TR);</li>\n      <li>Avidol (BD);</li>\n      <li>Betacard (PH);</li>\n      <li>Betaplex (CL);</li>\n      <li>Bicol (TR);</li>\n      <li>Bloquedil (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Blorec (ID);</li>\n      <li>Cadil (HR);</li>\n      <li>Caraten (TH);</li>\n      <li>Carbloxal (ID);</li>\n      <li>Cardilol (JO, LB, PH);</li>\n      <li>Cardine (SY);</li>\n      <li>Cardiol (FI, MY);</li>\n      <li>Cardipres (PH);</li>\n      <li>Cardivas (IN, VN);</li>\n      <li>Cardoz (LK, TZ);</li>\n      <li>Cargen (KR);</li>\n      <li>Carloc (ZA);</li>\n      <li>Carlov (PK);</li>\n      <li>Carsantin (VN);</li>\n      <li>Carved (BD);</li>\n      <li>Carvedexxon (IL);</li>\n      <li>Carvedil (EC);</li>\n      <li>Carvediteg (CR, GT, HN, NI, PA, SV);</li>\n      <li>Carvedlol (KR);</li>\n      <li>Carvelmed (VN);</li>\n      <li>Carvelol (KR, NZ);</li>\n      <li>Carvepen (SG);</li>\n      <li>Carveta (KR);</li>\n      <li>Carvid (PH);</li>\n      <li>Carvidex (MT, TR);</li>\n      <li>Carvidil (RU);</li>\n      <li>Carviditeg (DO);</li>\n      <li>Carvidol (CN, ET, JO, QA, SA);</li>\n      <li>Carvil (LK);</li>\n      <li>Carvilar (DO);</li>\n      <li>Carvo (TW);</li>\n      <li>Cavel (MY);</li>\n      <li>Coreg (BB, BM, BR, BS, BZ, GY, JM, SR, TT);</li>\n      <li>Coritensil (AR);</li>\n      <li>Coronis (ET);</li>\n      <li>Coropres (ES);</li>\n      <li>Corubin (EC);</li>\n      <li>Coryol (CO, CR, GT, NI, PA, RO, SV);</li>\n      <li>Dicarz (AU);</li>\n      <li>Dilabloc (PH);</li>\n      <li>Dilapress (LK);</li>\n      <li>Dilasig (AU);</li>\n      <li>Dilatrend (AE, AR, AT, AU, BF, BG, BH, BJ, CH, CI, CL, CN, CY, CZ, DE, EC, EE, EG, ET, GH, GM, GN, GR, HK, HR, HU, IT, JO, KE, KR, KW, LB, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NO, NZ, PE, PH, PL, PY, QA, RO, SA, SC, SD, SG, SL, SN, TH, TN, TR, TW, TZ, UG, UY, VE, VN, ZM, ZW);</li>\n      <li>Dilatrend SR (KR);</li>\n      <li>Dilbloc (PT);</li>\n      <li>Dilgard (BD);</li>\n      <li>Dimitone (DK);</li>\n      <li>Duobloc (PH);</li>\n      <li>Dylator (UA);</li>\n      <li>Eucardic (GB, NL);</li>\n      <li>Gladycor (MT);</li>\n      <li>Glovedol (PH);</li>\n      <li>Ictus (BR);</li>\n      <li>Karter (KR);</li>\n      <li>Karvedil (BD);</li>\n      <li>Karvil (ET, PH);</li>\n      <li>Karvydeks (UA);</li>\n      <li>Koriol (UA);</li>\n      <li>Kredex (AU, BE, FR, LU, SE);</li>\n      <li>Longcardio (TW);</li>\n      <li>Normotride (ES);</li>\n      <li>Querto (DE);</li>\n      <li>Riacavilol (SA);</li>\n      <li>Scodilol (VN);</li>\n      <li>Syntrend (TW);</li>\n      <li>Talliton (BB, BM, BS, BZ, GY, HK, JM, SR, TT, UA, VN);</li>\n      <li>Tocarlol (TH);</li>\n      <li>Udilol (TW);</li>\n      <li>V-Bloc (ID);</li>\n      <li>Vasodilren (KR);</li>\n      <li>Vedilol (AU, KR);</li>\n      <li>Volirop (AU);</li>\n      <li>Xetin (PY);</li>\n      <li>Xicard (PH);</li>\n      <li>Ziclar (PY)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins. ACOG Practice Bulletin. Chronic Hypertension in Pregnancy. ACOG Committee on Practice Bulletins. <i>Obstet Gynecol</i>. 2001;98(suppl 1):177-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/11508256/pubmed\" target=\"_blank\" id=\"11508256\">11508256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin. Diagnosis and Management of Preeclampsia and Eclampsia. Number 33, January 2002. <i>Obstet Gynecol</i>. 2002;99(1):159-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/16175681/pubmed\" target=\"_blank\" id=\"16175681\">16175681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Committee on Obstetric Practice. Committee Opinion No. 623: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. <i>Obstet Gynecol</i>. 2015;125(2):521-525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/25611642 /pubmed\" target=\"_blank\" id=\"25611642 \">25611642 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetricians and Gynecologists (ACOG), Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. <i>Obstet Gynecol</i>. 2013;122(5):1122-1131.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24150027 /pubmed\" target=\"_blank\" id=\"24150027 \">24150027 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amsterdam EA, Wenger NK, Brindis RG, et al; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association for Clinical Chemistry. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi: 10.1016/j.jacc.2014.09.017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/25260718/pubmed\" target=\"_blank\" id=\"25260718\">25260718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo; <i>Circulation</i>, 2011, 123(21):2434-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/21518977/pubmed\" target=\"_blank\" id=\"21518977\">21518977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baiges A, Hern&aacute;ndez-Gea V, Bosch J. Pharmacologic prevention of variceal bleeding and rebleeding. <i>Hepatol Int</i>. 2018;12(Suppl 1):S68-S80. doi: 10.1007/s12072-017-9833-y.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/29210030/pubmed\" target=\"_blank\" id=\"29210030\">29210030</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bhardwaj A, Kedarisetty CK, Vashishtha C, et al. Carvedilol delays the progression of small oesophageal varices in patients with cirrhosis: a randomised placebo-controlled trial. <i>Gut</i>. 2017;66(10):1838-1843. doi: 10.1136/gutjnl-2016-311735.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/27298379/pubmed\" target=\"_blank\" id=\"27298379\">27298379</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brauchli YB, Jick SS, Curtin F, et al, &ldquo;Association Between Beta-Blockers, Other Antihypertensive Drugs and Psoriasis: Population-Based Case-Control Study,&rdquo; <i>Br J Dermatol</i>, 2008, 158(6):1299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/18410416/pubmed\" target=\"_blank\" id=\"18410416\">18410416</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bristow MR, Gilbert EM, Abraham WT, et al, &ldquo;Carvedilol Produces Dose-Related Improvements in Left Ventricular Function and Survival in Subjects With Chronic Heart Failure,&rdquo; <i>Circulation</i>, 1996, 94(11):2807-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/8941106/pubmed\" target=\"_blank\" id=\"8941106\">8941106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Colucci WS, Packer M, Bristow MR, et al, &ldquo;Carvedilol Inhibits Clinical Progression in Patients With Mild Symptoms of Heart Failure. US Carvedilol Heart Failure Study Group,&rdquo; <i>Circulation</i>, 1996, 94(11):2800-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/8941105/pubmed\" target=\"_blank\" id=\"8941105\">8941105</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coreg (carvedilol immediate release) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coreg CR (carvedilol extended release) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dahlof B, Devereux RB, Kjeldsen SE, et al; Life Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. <i>Lancet</i>. 2002;359(9311):995-1003.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/11937178/pubmed\" target=\"_blank\" id=\"11937178\">11937178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dargie HJ, &ldquo;Effect of Carvedilol on Outcome After Myocardial Infarction in Patients With Left-Ventricular Dysfunction: The CAPRICORN Randomised Trial,&rdquo; <i>Lancet</i>, 2001, 357(9266):1385-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/11356434/pubmed\" target=\"_blank\" id=\"11356434\">11356434</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo; <i>Circulation</i>, 2012, 126(25):3097-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/23166211/pubmed\" target=\"_blank\" id=\"23166211\">23166211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster CA and Aston SJ, &ldquo;Propranolol-Epinephrine Interaction: A Potential Disaster,&rdquo; <i>Plast Reconstr Surg</i>, 1983, 72(1):74-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/6867180 /pubmed\" target=\"_blank\" id=\"6867180 \">6867180 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi: 10.1210/jc.2015-4061.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/26934393/pubmed\" target=\"_blank\" id=\"26934393\">26934393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. <i>Hepatology</i>. 2017;65(1):310-335. doi: 10.1002/hep.28906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/27786365/pubmed\" target=\"_blank\" id=\"27786365\">27786365</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Go AS, Bauman M, King SM, et al. An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [published online November 15, 2013]. <i>Hypertension</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24243703/pubmed\" target=\"_blank\" id=\"24243703\">24243703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatiti</i>s. 2002;47(5):312-313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/12534540/pubmed\" target=\"_blank\" id=\"12534540\">12534540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). <i>JAMA</i>. 2014;311(5):507-520.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24352797/pubmed\" target=\"_blank\" id=\"24352797\">24352797</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24682347/pubmed\" target=\"_blank\" id=\"24682347\">24682347</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Juul AB, Wetterslev J, Gluud C, et al, &ldquo;Effect of Perioperative Beta-Blockade in Patients With Diabetes Undergoing Major Non-Cardiac Surgery: Randomized Placebo Controlled, Blinded Multicentre Trial,&rdquo; <i>BMJ</i>, 2006, 332(7556):1482.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/16793810/pubmed\" target=\"_blank\" id=\"16793810\">16793810</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"14662257\"></a>Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? <i>J Am Coll Cardiol</i>. 2003;42(11):1944-1951.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/14662257/pubmed\" target=\"_blank\" id=\"14662257\">14662257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Krum H, Roecker EB, Mohacsi P, et al. Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS study. <i>JAMA</i>, 2003;289(6):712-718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/12585949/pubmed\" target=\"_blank\" id=\"12585949\">12585949</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Labrecque D, Dite P, Fried M, et al; World Gastroenterology Organisation. World Gastroenterology Organisation practice guideline: esophageal varices. http://www.worldgastroenterology.org/UserFiles/file/guidelines/esophageal-varices-english-2014.pdf. Published January 2014. Accessed September 20, 2016</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Laer S, Mir TS, Behn F, et al, &ldquo;Carvedilol Therapy in Pediatric Patients With Congestive Heart Failure: A Study Investigating Clinical and Pharmacokinetic Parameters,&rdquo; <i>Am Heart J</i>, 2002, 143(5):916-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/12040358/pubmed\" target=\"_blank\" id=\"12040358\">12040358</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo; <i>Drug Saf</i>, 1995, 12(5):299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/7669259/pubmed\" target=\"_blank\" id=\"7669259\">7669259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lennest&aring;l R, Otterblad Olausson P, K&auml;ll&eacute;n B. Maternal Use of Antihypertensive Drugs in Early Pregnancy and Delivery Outcome, Notably the Presence of Congenital Heart Defects in the Infants. <i>Eur J Clin Pharmacol</i>. 2009;65(6):615-625.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/19198819/pubmed\" target=\"_blank\" id=\"19198819\">19198819</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo; <i>J Card Fail</i>, 2010, 16(6):e1-194.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/20610207/pubmed\" target=\"_blank\" id=\"20610207\">20610207</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/10985636/pubmed\" target=\"_blank\" id=\"10985636\">10985636</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macdonald PS, Keogh AM, Aboyoun CL, et al, &ldquo;Tolerability and Efficacy of Carvedilol in Patients With New York Heart Association Class IV Heart Failure,&rdquo; <i>J Am Coll Cardiol</i>, 1999, 33(4):924-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/10091817/pubmed\" target=\"_blank\" id=\"10091817\">10091817</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P, Canadian Hypertensive Disorders of Pregnancy Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy: executive summary. <i>J Obstet Gynaecol Can</i>. 2014;36(5):416-441.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24927294 /pubmed\" target=\"_blank\" id=\"24927294 \">24927294 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi: 10.1161/CIR.0000000000000029.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24589852/pubmed\" target=\"_blank\" id=\"24589852\">24589852</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2013;127(4):e362-e425.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/23247304/pubmed\" target=\"_blank\" id=\"23247304\">23247304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer M, Bristow MR, Cohn JN, et al, &ldquo;The Effect of Carvedilol on Morbidity and Mortality in Patients With Chronic Heart Failure. U.S. Carvedilol Heart Failure Study Group,&rdquo; <i>N Engl J Med</i>, 1996, 334(21):1349-55.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/8614419/pubmed\" target=\"_blank\" id=\"8614419\">8614419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer M, Coats AJ, Fowler MB, et al, &ldquo;Effect of Carvedilol on Survival in Severe Chronic Heart Failure,&rdquo; <i>N Engl J Med</i>, 2001, 344(22):1651-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/11386263/pubmed\" target=\"_blank\" id=\"11386263\">11386263</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Packer M, Colucci WS, Sackner-Bernstein JD, et al, &ldquo;Double-Blind, Placebo-Controlled Study of the Effects of Carvedilol in Patients With Moderate to Severe Heart Failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise,&rdquo; <i>Circulation</i>, 1996, 94(11):2793-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/8941104/pubmed\" target=\"_blank\" id=\"8941104\">8941104</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    POISE Study Group, Devereaux PJ, Yang H, et al, &ldquo;Effects of Extended-Release Metoprolol Succinate in Patients Undergoing Non-Cardiac Surgery (POISE Trial): A Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2008, 371(9627):1839-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/18479744/pubmed\" target=\"_blank\" id=\"18479744\">18479744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Randomised, Placebo-Controlled Trial of Carvedilol in Patients With Congestive Heart Failure Due to Ischaemic Heart Disease. Australia/New Zealand Heart Failure Research Collaborative Group,&rdquo; <i>Lancet</i>, 1997, 349(9049):375-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/9033462/pubmed\" target=\"_blank\" id=\"9033462\">9033462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Redelmeier D, Scales D, and Kopp A, &quot;Beta Blockers for Elective Surgery in Elderly Patients: Population Based, Retrospective Cohort Study,&quot; <i>BMJ</i>, 2005, 331(7522):932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/16210252/pubmed\" target=\"_blank\" id=\"16210252\">16210252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2011;32(24):3147-3197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/21873418/pubmed\" target=\"_blank\" id=\"21873418\">21873418</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiberger T, Ulbrich G, Ferlitsch A,et al; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i>. 2013;62(11):1634-1641.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/23250049/pubmed\" target=\"_blank\" id=\"23250049\">23250049</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanyal AJ. Primary and pre-primary prophylaxis against variceal hemorrhage in patients with cirrhosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc.http://www.uptodate.com. Accessed March 6, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sch&ouml;n MP and Boehncke WH, &ldquo;Psoriasis,&rdquo; <i>N Eng J Med</i>, 2005, 352(18):1899-1912.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/15872205/pubmed\" target=\"_blank\" id=\"15872205\">15872205</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/7746084/pubmed\" target=\"_blank\" id=\"7746084\">7746084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinagra E, Perricone G, D'Amico M, Tin&egrave; F, D'Amico G. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. <i>Aliment Pharmacol Ther</i>. 2014;39(6):557-568. doi: 10.1111/apt.12634.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24461301/pubmed\" target=\"_blank\" id=\"24461301\">24461301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>Eur J Heart Fail</i>. 2010;12(8):767-778.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/20675664 /pubmed\" target=\"_blank\" id=\"20675664 \">20675664 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. <i>Hepatology</i>. 2009;50(3):825-833.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/19610055/pubmed\" target=\"_blank\" id=\"19610055\">19610055</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    UK Prospective Diabetes Study Group, &ldquo;Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 39,&rdquo; <i>BMJ</i>, 1998, 317(7160):713-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/9732338/pubmed\" target=\"_blank\" id=\"9732338\">9732338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weber MA, Schiffrin EL, White WB, et al, Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. <i>J Clin Hypertens (Greenwich)</i>. 2014;16(1):14-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/24341872/pubmed\" target=\"_blank\" id=\"24341872\">24341872</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong DG, Spence JD, Lamki L, et al, &ldquo;Effect of Nonsteroidal Anti-inflammatory Drugs on Control of Hypertension of Beta-Blockers and Diuretics,&rdquo; <i>Lancet</i>, 1986, 1(8488):997-1001.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/2871333 /pubmed\" target=\"_blank\" id=\"2871333 \">2871333 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wynn RL, &ldquo;Epinephrine Interactions With Beta-Blockers,&rdquo; <i>Gen Dent</i>, 1994, 42(1):16, 18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/7911769 /pubmed\" target=\"_blank\" id=\"7911769 \">7911769 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America [published online May 20, 2016]. <i>Circulation</i>. doi: 10.1161/CIR.0000000000000435.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/27208050/pubmed\" target=\"_blank\" id=\"27208050\">27208050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yang H, Raymer K, Butler R, et al, &ldquo;The Effects of Perioperative Beta-Blockade: Results of the Metoprolol After Vascular Surgery (MaVS) Study, A Randomized Controlled Trial,&rdquo; <i>Am Heart J</i> 2006, 152(5):983-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/carvedilol-drug-information/abstract-text/17070177/pubmed\" target=\"_blank\" id=\"17070177\">17070177</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9208 Version 263.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F146697\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F146698\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F146742\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F146702\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F146703\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F146704\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F146705\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F146669\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F146653\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23610321\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F146673\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F146672\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25724865\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F146750\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F146660\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F146676\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F146657\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F146735\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F146662\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F146692\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F146680\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10162397\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F146681\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F146667\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F146656\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F146675\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F146679\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F146682\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9208|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=carvedilol-patient-drug-information\" class=\"drug drug_patient\">Carvedilol: Patient drug information</a></li><li><a href=\"topic.htm?path=carvedilol-pediatric-drug-information\" class=\"drug drug_pediatric\">Carvedilol: Pediatric drug information</a></li></ul></div></div>","javascript":null}